JA Aberg

Learn More
BACKGROUND The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. METHODS VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INI-resistant virus received(More)
Background: Toll-like receptors (TLRs) are transmembrane receptors that activate cells of the innate immune systems upon recognition of pathogen-associated molecular patterns. The TLR4 is an essential component of the innate immune response to various microorganisms. We investigated the impact of TLR4 polymorphism on development of opportunistic diseases in(More)
Purpose Protease inhibitors may contribute to metabolic complications and cardiovascular risk associated with HIV infection. Here we investigate metabolic changes following treatment with darunavir/ritonavir (DRV/r)-compared with atazanavir/ritonavir (ATV/r)-based therapy. Methods In this 48-week, Phase IV, multicenter, open-label, ran-domized, exploratory(More)
  • 1